Immunometabolic Dysregulation in Psoriasis: Mechanisms Driving Inflammation and Emerging Therapeutic Targets - PubMed
4 hours ago
- #Psoriasis
- #Immunometabolism
- #Therapeutic Targets
- Psoriasis is recognized as a systemic immuno-metabolic disorder involving chronic inflammation and cellular energy metabolism alterations.
- Metabolic reprogramming in psoriatic cells includes increased glycolysis, altered lipid metabolism, mitochondrial dysfunction, and excessive reactive oxygen species production.
- These metabolic disturbances contribute to keratinocyte hyperproliferation and sustain Th17-driven inflammation, linking skin pathology with systemic comorbidities like obesity and insulin resistance.
- Key regulators such as mTOR, AMPK, HIF-1α, SIRT1, and PGC-1α integrate metabolic status with inflammatory signaling.
- Adipokine imbalance and metabolic stress promote chronic metaflammation.
- Potential therapeutic targets include glycolysis inhibitors, AMPK activators, mTOR modulators, mitochondrial-targeted antioxidants, and lipid-regulating agents.
- Multi-omics approaches may enhance biomarker discovery and precision-based therapeutic strategies in psoriasis management.